Clinical Trials Directory

Trials / Completed

CompletedNCT01320449

Identification of New Serum Markers for Detection of Abuse With Erythropoietin

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
35 (actual)
Sponsor
University of Aarhus · Academic / Other
Sex
Male
Age
18 Years – 35 Years
Healthy volunteers
Accepted

Summary

Epo increases red blood cell production and hence the amount of oxygen that can be transported around the body. It is shown that prolonged use of synthetic Epo (rHuEpo) leads to an increase in the period of time a given physical work can be performed, therefore it will continue to be abused by athletes, especially in endurance sports. The existing method for measuring the abuse of rHuEpo approved by the World Anti-Doping Agency (WADA) is based on differences in the sugar groups bound to rHuEpo and Epo produced in the body, respectively. Proteomics is a method by which one can look at all the proteins in blood at the same time. Even proteins that have changed very little can be distinguished. The main objective of this project is to investigate the effect of prolonged treatment with rHuEpo on changes in blood proteins in healthy young men.

Conditions

Interventions

TypeNameDescription
DRUGrecombinant human erythropoietinrHuEpo (5000 IU)is administered using a small syringe under the skin every other day for the first 2 weeks, on 3 consecutive days during week 3, and once a week from week 4-10.
BEHAVIORALTrainingFor ten weeks participants will receive supervised endurance training on a bike three times a week. Physical effect will be examined with VO2-max tests before during and after the training period.
OTHERPlaceboplacebo (saline) is administered using a small syringe under the skin every other day for the first 2 weeks, on 3 consecutive days during week 3, and once a week from week 4-12.

Timeline

Start date
2011-08-01
Primary completion
2012-07-01
Completion
2012-07-01
First posted
2011-03-22
Last updated
2012-08-01

Locations

2 sites across 1 country: Denmark

Source: ClinicalTrials.gov record NCT01320449. Inclusion in this directory is not an endorsement.